{"version":"1.0","type":"link","title":"Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.","author_name":"Mehra N 외","author_url":"https://prs-insight.online/author/Mehra%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/137338","thumbnail_width":1200,"thumbnail_height":630}